Objective: Most acute ischemic stroke (AIS) patients with unwitnessed symptom onset are ineligible for intravenous thrombolysis due to timing alone. Lesion evolution on fluid-attenuated inversion recovery (FLAIR) magnetic resonance imaging (MRI) correlates with stroke duration, and quantitative mismatch of diffusion-weighted MRI with FLAIR (qDFM) might indicate stroke duration within guideline-recommended thrombolysis. We tested whether intravenous thrombolysis 4.5 hours from the time of symptom discovery is safe in patients with qDFM in an open-label, phase 2a, prospective study (NCT01282242). Methods: Patients aged 18 to 85 years with AIS of unwitnessed onset at 4.5 to 24 hours since they were last known to be well, treatable within 4.5 hours of symptom discovery with intravenous alteplase (0.9mg/kg), and presenting with qDFM were screened across 14 hospitals. The primary outcome was the risk of symptomatic intracranial hemorrhage (sICH) with preplanned stopping rules. Secondary outcomes included symptomatic brain edema risk, and functional outcomes of 90-day modified Rankin Scale (mRS). Results: Eighty subjects were enrolled between January 31, 2011 and October 4, 2015 and treated with alteplase at median 11.2 hours (IQR 5 9.5-13.3) from when they were last known to be well. There was 1 sICH (1.3%) and 3 cases of symptomatic edema (3.8%). At 90 days, 39% of subjects achieved mRS 5 0-1, as did 48% of subjects who had vessel imaging and were without large vessel occlusions. Interpretation: Intravenous thrombolysis within 4.5 hours of symptom discovery in patients with unwitnessed stroke selected by qDFM, who are beyond the recommended time windows, is safe. A randomized trial testing efficacy using qDFM appears feasible and is warranted in patients without large vessel occlusions.
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Objective: Most acute ischemic stroke (AIS) patients with unwitnessed symptom onset are ineligible for intravenous thrombolysis due to timing alone. Lesion evolution on fluid-attenuated inversion recovery (FLAIR) magnetic resonance imaging (MRI) correlates with stroke duration, and quantitative mismatch of diffusion-weighted MRI with FLAIR (qDFM) might indicate stroke duration within guideline-recommended thrombolysis. We tested whether intravenous thrombolysis 4.5 hours from the time of symptom discovery is safe in patients with qDFM in an open-label, phase 2a, prospective study (NCT01282242). Methods: Patients aged 18 to 85 years with AIS of unwitnessed onset at 4.5 to 24 hours since they were last known to be well, treatable within 4.5 hours of symptom discovery with intravenous alteplase (0.9mg/kg), and presenting with qDFM were screened across 14 hospitals. The primary outcome was the risk of symptomatic intracranial hemorrhage (sICH) with preplanned stopping rules. Secondary outcomes included symptomatic brain edema risk, and functional outcomes of 90-day modified Rankin Scale (mRS). Results: Eighty subjects were enrolled between January 31, 2011 and October 4, 2015 and treated with alteplase at median 11.2 hours (IQR 5 9.5-13.3) from when they were last known to be well. There was 1 sICH (1.3%) and 3 cases of symptomatic edema (3.8%). At 90 days, 39% of subjects achieved mRS 5 0-1, as did 48% of subjects who had vessel imaging and were without large vessel occlusions. Interpretation: Intravenous thrombolysis within 4.5 hours of symptom discovery in patients with unwitnessed stroke selected by qDFM, who are beyond the recommended time windows, is safe. A randomized trial testing efficacy using qDFM appears feasible and is warranted in patients without large vessel occlusions. ANN NEUROL 2018; 83:980-993 I ntravenous (IV) thrombolysis of acute ischemic stroke (AIS) with recombinant tissue plasminogen activator (alteplase) is the only guideline-recommended IV AIS therapy, and it must be administered 4.5 hours from when the patient was last known to be well. Despite 2 decades of availability, IV alteplase is given to <10% of patients worldwide. 1 One reason for underuse is the strict time restriction. Although time is easily measured, onset of symptoms is frequently not witnessed and difficult to establish in the emergency department setting; approximately 25 to 30% of AIS patients have stroke with unwitnessed symptom onset. 2 Despite rapid presentation to the emergency department following symptom discovery, these patients do not qualify for guidelinerecommended IV alteplase due to arrival >4.5 hours from when the patient was last known to be well, and most lack large vessel occlusions (LVOs) required for endovascular thrombectomy. Even among stroke patients arriving at hospitals <6 hours after they were last known to be well, <2% currently receive endovascular thrombectomy. 3, 4 These numbers will likely increase due to several major trials showing profound benefit of endovascular thrombectomy. 5 Recent clinical trial results 6, 7 suggest that endovascular thrombectomy for patients with unwitnessed strokes and LVOs is beneficial, and it is likely that this treatment approach that is now recommended will increasingly be adopted for unwitnessed LVO strokes. With increased screening of patients with unwitnessed strokes up to 24 hours since they were last known to be well, there is urgent need to find effective new treatments for patients with unwitnessed strokes who lack LVOs.
Retrospective studies of stroke patients with unwitnessed symptom onset treated with IV thrombolysis on a compassionate basis found that thrombolysis may be safely administered in a select subset with imaging patterns consistent with early stroke. 8, 9 Small single center studies using imaging selection for prospectively treating stroke patients with unwitnessed symptom onset showed similar safety. 10, 11 These studies suggested that a magnetic resonance imaging (MRI) diffusion-fluidattenuated inversion recovery (FLAIR) mismatch, that is, the presence of hyperintensity on diffusion-weighted MRI (DWI) with minimal or no evidence of hyperintensity on corresponding T2-weighted FLAIR images, might identify a group of patients in whom the biological onset of symptom is more closely approximated by time of symptom discovery rather than time the patient was last known to be well. This supports FLAIR imaging being used as a "tissue clock" for ischemic injury, because its signal intensity increases over time after AIS, as has been demonstrated in experimental animal models. 12 Therefore, diffusion-FLAIR mismatch might characterize stroke that is within 4.5 hours of biological symptom onset. 13 Diffusion-FLAIR mismatch has not yet been shown in a prospective multicenter study to be able to independently safely select patients for thrombolysis. In addition, simple qualitative diffusion-FLAIR mismatch has poor interrater agreement 13 and hence might not be reproducible in a multicenter setting. We improved diffusion-FLAIR mismatch reproducibility 14 by requiring that abnormal FLAIR be quantified; we hypothesized that a quantitative diffusion-FLAIR mismatch (qDFM) can be used in place of time since the patient was last known to be well to identify stroke patients with unwitnessed symptom onset who can safely be treated with thrombolytic therapy. The DWI-positive and FLAIRnegative pattern proposed as a surrogate for short duration since symptom onset in our study is consistent with a pattern of restricted apparent diffusion coefficient with normal T2 signal that characterizes compromised tissue that may or may not recover with reperfusion as validated against histopathology in experimental stroke models. 15, 16 Furthermore, the presence of hyperintense FLAIR lesions, in addition to being a possible indicator of late stage strokes, has also been linked to increased symptomatic intracranial hemorrhage (sICH) risk even in patients treated within 3 hours. 17 Therefore, by excluding patients with substantial acute FLAIR lesions, we also excluded those patients with stroke deficits severe enough to have substantially delayed their initial presentation to medical assistance. Thus, qDFM is representative of not only short duration since symptom onset but also tissue with the greatest likelihood of recovery with reperfusion.
Prior to initiation of a randomized placebocontrolled trial (RCT) investigating the safety and efficacy of thrombolysis in imaging-selected stroke patients with unwitnessed symptom onset, a multicenter prospective phase 2a study was necessary to prove feasibility of acute MRI-based qDFM enrollment and of screening up to 24 hours since the patient was last known to be well, and to provide definitive evidence of safety of thrombolysis in this population. In stroke patients with unwitnessed symptom onset and qDFM, time subject was last known to be well could be replaced by time of discovery of symptoms and used in the treatment decision for thrombolysis. Therefore, the trial design contained both a time-based constraint (by requiring treatment within 4.5 hours from first detection of symptoms), as well as a tissue-based constraint (qDFM). Both conditions needed to be met for enrollment in this trial. When the study was first formulated in 2009, MR WITNESS was designed based on the hypothesis that qDFM could be used to safely select patients with limited tissue injury due to brief stroke duration who might benefit from reperfusion, assuming that tissue infarction progresses at a relatively constant rate after symptom onset in most patients. As this was a safety study, it seemed prudent to constrain the upper limit of time since discovery of symptoms, to align with the available data on the known therapeutic time window of safety and efficacy of IV thrombolysis and the known risk of harm with delayed treatment. Our strategy was to enrich the study population with those subjects that likely still had brain at risk that could be salvaged by acute IV thrombolysis, as we believe that a substantial number of patients who awaken with symptoms do so shortly after the biological onset of their symptoms and patients with unwitnessed strokes might similarly have had symptom onset close to symptom discovery time. If our approach is successful, subsequent trials of IV thrombolysis could explore whether time since the patient was last known to be well or symptom discovery could ultimately be abandoned, with treatment decisions based purely on brain imaging findings.
We therefore conducted the MR WITNESS trial using an imaging-based "magnetic resonance (MR) witness" of infarct evolution rather than a "human witness" of chronologic time. We designed our subject selection criteria to select subjects who would be similar in stroke evolution to those treated in the ECASS3 trial, a trial that showed benefit from IV thrombolysis when given 3 to 4.5 hours after symptom onset. We therefore excluded subjects with symptom discovery > 4.5 hours previous. Although there may exist patients who are >4.5 hours since symptom discovery but in whom ischemia progresses much more slowly than expected and who still have a qDFM pattern that might benefit from thrombolysis, numerous independent studies have shown that such patients with diffusion-FLAIR mismatch > 6 hours after stroke onset are extremely rare. 18 Our study was not designed to assess whether those who have greater stroke duration chronologically but who are slow progressors will respond to thrombolysis. Future studies that select subjects purely by imaging without regard to symptom discovery time will be needed to test this hypothesis.
Subjects and Methods

Study Design and Participants
We conducted a multicenter, phase 2a, open-label safety trial of intravenous thrombolysis in stroke patients with unwitnessed symptom onset (ClinicalTrials.gov, NCT01282242). The study was conducted under an investigational new drug (IND) application with the U.S. Food and Drug Administration (FDA; IND 110075, 110088) and approved by the local institutional review board of each participating site. The trial launched with 3 sites and expanded in 2 waves to include a total of 14 U.S. sites. The full study protocol including imaging details is available at http:// www.mrwitness.org. Patients were recruited from the emergency department and inpatient areas. Each study site screened patients with unwitnessed symptom onset who were last known to be well between 4.5 hours to 24 hours previously and could receive treatment within 4.5 hours of symptom discovery. At trial onset, subjects were excluded from the trial using criteria similar to the guideline-recommended exclusions in the United States for IV alteplase in the 3-to 4.5-hour window, including severe stroke as assessed clinically (eg, National Institutes of Health Stroke Scale [NIHSS] score > 25) or by appropriate imaging techniques (DWI lesion volume > one-third of middle cerebral artery by visual inspection or > 100cm 3 using the ellipsoid estimation formula of ABC/2 (where A, B and C refer to the diameters of the ellipsoid shape of the infarct, as measured in the mathematical orthogonal planes)). After new data suggested safety of thrombolysis at 3 to 4.5 hours in clinical practice, in 2012 the age limit was raised from 80 to 85 years and the exclusion for diabetes plus stroke was removed.
Patients with a history of recent dabigatran use but none in the past 24 hours and with normal clotting studies were deemed eligible under specific circumstances. As this was a safety study, we did not exclude patients with prestroke disability (modified Rankin Scale [mRS] > 1). Additional MR-specific exclusion criteria were uninterpretable images, lack of DWI lesion, evidence of prior macroscopic intracranial hemorrhage (ICH), or microbleeds in a pattern suggestive of amyloid angiopathy. Full clinical and imaging inclusion and exclusion criteria can be found in the study protocol and in the Supplementary Materials. Prior to enrollment, all clinically eligible patients underwent MRI. Eligible subjects were 18 to 85 years of age, had a disabling neurological deficit at time of treatment lasting at least 30 minutes, had a confirmed ischemic stroke on MRI, and had a qDFM pattern, defined as minimal or no hyperintensity on FLAIR imaging in a region corresponding to that of restricted diffusion on DWI. The acceptable threshold for minimal FLAIR hyperintensity was specified a priori as a signal intensity ratio (SIR) of < 1.15 when the mean signal intensity measured in a region of interest (ROI) involving the FLAIR hyperintensity was divided by a corresponding mean signal intensity in an ROI in normal-appearing tissue in the contralesional hemisphere.
14 Figure 1 shows the imaging-based selection algorithm.
Study Procedures
The schedule of assessments for enrolled subjects is shown in Figure 2 . Written informed consent was obtained prior to thrombolysis. Alteplase was administered at the usual dose and method of 0.9mg/kg (maximum dose 90mg) with 10% as a bolus over 1 minute and the remainder by continuous infusion over 1 hour. The duration of the study was 90 6 14 days. Demographics, medical history, and clinical and laboratory data were collected. Demographics consisted of age, sex, race, and ethnicity. Medical history included atrial fibrillation, coronary artery disease, myocardial infarction, peripheral arterial disease, carotid stenosis, diabetes mellitus, dyslipidemia, congestive heart failure, hypertension, renal insufficiency, chronic obstructive pulmonary disease, prior stroke or transient ischemic attack, dementia, and smoking. Laboratory factors included initial international normalized ratio (INR) and blood glucose. Systolic blood pressure and diastolic blood pressure at admission were used. Neurological assessments consisted of NIHSS, mRS, and Barthel Index (BI). NIHSS was required at all designated time-points except the 90-day visit, where a telephone interview was allowed. The last NIHSS score prior to treatment was entered as the initial NIHSS; if not repeated, arrival NIHSS was used. BI and mRS were performed at hospital discharge, and 30-day and 90-day visits. Stroke subtype was performed using TOAST (Trial of Org 10172 in Acute Stroke Treatment) classification.
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Image Acquisition, Triage, and Analysis
All clinically eligible patients underwent at minimum DWI, FLAIR, and gradient echo T2*-weighted sequences. Angiography and perfusion sequences were optional. An imaging protocol provided to all sites prior to site initiation contained recommended imaging acquisition parameters (see Supplementary Materials). All sites submitted a description of their protocol of standard stroke imaging to the Imaging Core and were provided feedback if the protocol parameters were outside of the suggested acquisition parameters. Feedback was sent to the site if images acquired during the trial deviated beyond the suggested parameters. Prior to receiving study drug, at least 1 reader at each site was required to pass training and certification by the Imaging Core. Each reader was provided an initiation packet containing 10 training cases and 20 test cases from patients with witnessed symptom onset as well as instructions for avoiding selecting chronic lesions. Correct classification results and sample ROIs were provided for the 10 training cases to each reader. Readers sent their classification results for the 20 test cases to the Imaging Core for grading. Before readers were considered trained and certified for performing imaging eligibility assessment for MR WITNESS, they had to obtain an intraclass correlation of at least 0.80 on signal intensity measurements and Fleiss kappa (j 0.80) on the qDFM classifications for the 20 test cases against the Imaging Core results. Prior to certification, readers were required to send a screenshot demonstrating their ability to perform real-time signal intensity ratio measurement to the Imaging Core.
Outcomes
The primary outcome was safety of IV alteplase, using the European Cooperative Acute Stroke Study (ECASS)-2 sICH definition (ie, any blood in the brain on computed tomography [CT] and an NIHSS score that was higher by 4 points than the value at baseline or the lowest value in the first 7 days, or any hemorrhage leading to death). 20 This sICH definition was chosen to avoid bias because this was an open-label safety trial.
We assessed safety at prespecified interim analyses that tested whether the sICH risk was >5.3%, and at completion whether the sICH risk was significantly <5.3%. A secondary safety outcome was the risk of symptomatic brain edema, defined as brain edema with mass effect as the predominant cause of clinical deterioration, relative to the ECASS-3 risk of 6.9%. 21 We chose to investigate symptomatic edema as a secondary safety outcome because it is a known potential risk of late reperfusion. 22, 23 All images were screened for hemorrhagic transformation (HT) by the neuroimaging core, adjudicated by 2 boardcertified neuroradiologists (A.J.Y., M.H.L.) who resolved discordant readings by consensus. HT was prespecified to be classified using the ECASS-1 criteria: hemorrhagic infarction (HI) type 1 (HI-1; nonconfluent punctate foci within infarcted tissue), HI type 2 (HI-2; confluent foci or linear areas of signal loss within FIGURE 2: Trial Profile. *This number only includes patients deemed clinically eligible to undergo magnetic resonance imaging (MRI) screening. Other patients were not systematically tracked. The total does not include patients who refused study participation despite meeting MRI eligibility criteria (n 5 4). **At 1 site, the 24-hour imaging study was performed using MRI per site protocol. †Five subjects died by the assessment at 30 6 7 days. ‡Seven subjects died by the assessment at 90 6 14 days. CT 5 computed tomography.
the infarcted area), parenchymal hemorrhage (PH) type 1 (PH-1; PH < 1/3 of the infarcted area), PH type 2 (PH-2; PH > 1/3 of the infarcted area). 24 Hemorrhagic lesions distant from the infarcted area were all rated remote PH (RPH) type 1 (RPH-1) or type 2 (RPH-2) according to the absence or presence of significant mass effect, respectively. Presence of intraventricular and subdural hemorrhages was also noted. The HT type was also categorized post hoc according to the Heidelberg Bleeding Classification criteria to facilitate comparisons to future studies. 5 In cases with > 1 type of HT occurring simultaneously (class 1 and class 3), the more severe category was used (class 3). Adverse events were classified per FDA criteria and are listed at ClinicalTrials.gov NCT01282242. An independent medical monitor reviewed all cases of ICH and significant brain edema to classify them as symptomatic or asymptomatic, and reported the findings to an independent 3-person data safety monitoring board (DSMB). The DSMB reviewed every case of sICH or serious adverse event and applied a set of prespecified stopping rules to determine whether the trial should continue. Asymptomatic ICH (aICH) risk at 24 hours was also evaluated. An additional secondary objective was assessment of good outcome, which was prespecified as mRS 5 0-1 at 90 days. Last observation carried forward was used for mRS outcomes that were not available at 90 days.
Statistical Analyses
The primary outcome of sICH was based on the adjudicated sICH assessments. The stopping boundary for the trial was a hybrid of 2 conditions: (1) if the lower 95% confidence interval (CI) of the hemorrhage risk observed in MR WITNESS was >5.3%, or (2) if the absolute number of sICH cases exceeded 6 during the trial. A sample size of 80 was calculated based on simulations (5,000 repetitions) of hemorrhages as binary random variables and calculation of the exact 95% lower confidence bound, such that if the true hemorrhage risk were 5.3%, the study would detect a safety problem with probability 5 0.15, if the true risk was 8% it would detect a problem with probability 5 0.49, and if the true risk was 10% it would detect a problem with probability 5 0.68. At trial completion, we had 80% power using a 1-sided, 0.2 significance level exact binomial test to detect a symptomatic edema risk of 12.5% or larger, assuming a symptomatic edema rate of 6.9% as seen in ECASS-3 treated patients.
Following successful trial completion, as secondary analyses, we performed 1-sided, 1-sample exact binomial tests to assess whether the risks of sICH and symptomatic edema were larger than those from ECASS-3. All other comparisons with ECASS-3 are based on 2-sided Fisher exact tests, treating ECASS-3 as an independent group. Univariate comparisons between outcome groups and variables of interest were conducted using Fisher exact tests for categorical variables and exact Wilcoxon rank sum tests (100,000 Monte Carlo repetitions) for continuous variables. Proportions are provided with 95% exact binomial CIs. Univariate logistic regressions were performed to estimate the associations between variables of interest and good outcomes (mRS 5 0-1) at 90 days, and aICH at 24 hours, and multiple logistic regression models were fitted with all variables with p < 0.10 in univariate logistic regressions. Variables without cases in the predicted outcome group (ie, with "complete separation") were not considered as candidates for multiple regression. All odds ratio (OR) estimates are presented with 95% Wald CIs. Relative risk (RR) was calculated when comparing MR WITNESS results with respect to ECASS-3 results. Stroke subtype was dichotomized into lacunar versus nonlacunar. Subjects with documented medical conditions (eg, hypertension), behaviors (eg, current smoker), or wakeup strokes were classified as such; those without explicit documentation were assigned the absence of conditions. To assess the impact of variables for which some subjects had missing values or were coded as "not documented," we conducted sensitivity analyses in which all such cases were removed. We also conducted subgroup analyses for safety and efficacy among those subjects who underwent vessel imaging and who did not have an LVO of the internal carotid artery or M1 segment of the middle cerebral artery (ICA/M1). All analyses were conducted in SAS 9.4.
Results
Between January 31, 2011 and October 4, 2015, 183 patients were screened to enroll 80 subjects (see Fig 2) . Figure 3 shows imaging examples of an enrolled (A) and an excluded (B) subject based on applying the qDFM imaging criteria. Baseline characteristics are shown in Table 1 . Only medical history factors that differed between patients with good outcome (mRS 1) and poor outcome (mRS 2) with p 0.10 are shown. The full table of results can be found in the Supplementary Materials. Among sites that recruited for >1 year, median enrollment was 3.12 patients per year (interquartile ratio [IQR] 5 1.78-4.47). Of the enrolled subjects, 40 of 80 (50.0%, 95% confidence interval [CI] 38.6-61.4%) were FLAIR positive. Vessel imaging was obtained at presentation in 70 subjects, of whom 16 (22.9%) exhibited an ICA/M1 LVO potentially treatable with endovascular thrombectomy. There was 1 stroke mimic enrolled for a proportion of 1 of 80 (1.3%, 95% CI 5 0.0-6.8%). Our median arrival-to-thrombolysis time was 1.78 hours, and MRI-to-thrombolysis time was 0.9 hours. Because subjects or their surrogates provided consent for participation in the study after a routine MRI was acquired and screened for eligibility, comparing imaging to needle times between this study and clinical care is reasonable, but the door to needle times in our study include consent and thus are most appropriately compared to other thrombolysis trials that required consent. The primary outcome was safety, measured as sICH, which was observed in 1 of 80 cases, and was classified as a PH-2 (1.3%, 95% CI 5 0.0-6.8%). This was not different from the ECASS-3 risk of 22 17.2%) subjects, which was not different from the ECASS-3 risk of 32 of 418 (7.7%, RR 5 1.14, p 5 0.66).
At 90-day follow-up, the median BI was 95 (IQR 5 75-100). The median 90-day mRS was 2 (IQR 5 1-3), improving from 4 (IQR 5 2-4) at discharge and 3 (IQR 5 1-4) at 30-day (1 subject had no 90-day visit, so the 30-day mRS score was carried forward). Among the 80 subjects enrolled, 31 of 80 (38.8%, 95% CI 5 28.1-50.3%) had a good 90-day outcome (see Fig 2) . On univariate testing, there was no difference in outcome between subjects with or without aICH at 24 hours, or between those with wakeup versus nonwakeup stroke, and no patients with dementia had good outcome (see Table 1 ). Only pre-existing disability prior to stroke, lacunar subtype, hypertension, current smoking, systolic blood pressure, blood glucose, MRI-tothrombolysis time, arrival-to-MRI time, and initial NIHSS were significant at p < 0.10. When these covariates were included in multiple logistic regression, only absence of prestroke disability, nonlacunar subtype, nonsmoking, and lower initial NIHSS remained significantly associated with good outcome (Table 2) . Among the 69 subjects with prestroke mRS 5 0-1, 30 of 69 (43.5%, 95% CI 5 31.6-56.0%) had good 90-day outcome (Fig  4) , and univariate and multiple regression analyses produced similar results to the full 80-subject cohort (data not shown). In the subgroup of 70 subjects with vessel imaging, a larger proportion of subjects with excellent outcome occurred in the group without ICA/M1 LVOs compared to the group with ICA/M1 LVOs (p 5 48.1% vs 18.8%, OR 5 4.02, p 5 0.045).
Sensitivity analyses for good 90-day outcomes generated similar results. In univariate logistic regression, hypertension and systolic blood pressure were no longer significant at p < 0.10, and dyslipidemia became significant (OR 5 0.44, p 5 0.095). Multiple regression produced similar results for variables with p < 0.05. Among the 69 subjects with prestroke mRS 5 0-1, hypertension was no longer significant in univariate logistic regression, but sensitivity analysis and multiple logistic regression provided similar results. Of the 54 subjects without ICA/M1 LVOs (see Supplementary Materials), hypertension and blood glucose were no longer significant in univariate logistic regression, but race remained significant. However, multiple logistic regression produced similar results (see Supplementary Materials). Sensitivity analysis generated the same set of significant variables in both univariate and multivariate settings for good 90-day outcome. Among the 46 subjects with prestroke mRS 5 0-1, NIHSS and hypertension were no longer significant in the univariate setting. In the multivariate model including variables that were significant in univariate analyses (lacunar stroke, current smoker, and systolic blood pressure), only current smoker was significant (OR 5 0.10, p 5 0.01).
On univariate testing for predictors of aICH at or before 24 hours among the 79 subjects without sICH, symptom discovery to thrombolysis duration, history of atrial fibrillation, initial INR, and initial NIHSS were significant at p < 0.10 (Table 3 ; see Supplementary Materials for full results). When these covariates were included in multiple logistic regression, only initial NIHSS remained significantly associated with aICH (Table 4) . Sensitivity analysis identified congestive heart failure (OR 5 5.16, p 5 0.09) and wake-up stroke (OR 5 0.37, p 5 0.08) in addition to those reported above. In multiple regression, as in the main analysis, only NIHSS remained significant at p < 0.05. Similar multivariate results were observed for the 53 subjects without ICA/ M1 LVOs or sICH (see Supplementary Materials), resulting in only NIHSS as a significant predictor of aICH at 24 hours. Sensitivity analysis for multiple logistic regression resulted in no variable significant at the p < 0.05 level (NIHSS OR 5 1.42, p 5 0.06).
Discussion
We present the results of the first prospective study of the safety of IV thrombolysis for strokes with unwitnessed symptom onset selected using qDFM. We showed that in this population, IV alteplase administered within 4.5 hours of symptom discovery did not increase the risks of sICH, symptomatic brain edema, aICH, or mortality when compared to the thrombolysis arm of the ECASS-3 trial. In addition, we showed that using qDFM can potentially double the enrollment rate over using qualitative diffusion-FLAIR mismatch without affecting rate of good outcomes and sICH. Our enrollment rate for sites enrolling over 1 year was similar to that of FIGURE 4: Modified Rankin Scale (mRS) scores at day 90 in all treated subjects (n 5 80), and in the subset of subjects (n 5 69) who were without disability (mRS 5 0-1) prior to the index stroke.
another prospective wakeup stroke study that used CT for inclusion. 25 Furthermore, our median time from start of MRI to initiation of thrombolysis was <1 hour, including time for consent. This demonstrates the feasibility of using our qDFM approach expeditiously in clinical situations for which informed consent will not be required prior to initiation of treatment. Our prospective study confirms the safety of IV alteplase that was suggested by prior retrospective, and small prospective, studies. Since our study launched in 2011, there have been several new trials involving subjects with unwitnessed symptom onset that have been initiated to investigate efficacy 26, 27 or that have been completed. One of the recently completed studies used CT to select wakeup stroke patients in an open-label trial involving 5 centers (n 5 40) and found no cases of sICH. 25 A single center study involving 20 wakeup stroke subjects (with Alberta Stroke Program Early CT score > 5 and angiographic or ultrasound evidence of arterial occlusion) showed similar results. 28 Other Data are mean 6 standard deviation, n (%), or median (interquartile range). The 1 subject with symptomatic ICH was excluded from this analysis. a The stroke mimic who had no ICH was excluded, because no stroke subtype could be assigned. b Statistically significant at p < 0.05. c Subjects were assumed not to have the condition unless it was explicitly documented in their medical record. d Two subjects were missing initial INR in the no-ICH group. e Excluding 1 subject with symptom discovery after arrival. prospective studies involving delayed thrombolysis (>4.5 hours from when the patient was last known to be well) of wakeup and nonwakeup unwitnessed stroke patients based on CT perfusion 29, 30 or qualitative diffusion-FLAIR mismatch 31 had no cases of sICH. However, none of these studies [29] [30] [31] was designed to test for safety or efficacy of thrombolysis. One prospective multicenter study with 6 centers that treated 83 subjects with unwitnessed symptom onset within 6 hours of symptom discovery time reported an sICH risk of 6%. 32 However, this study required presence of DWI and perfusion-MRI mismatch for patient enrollment, and absence of DWI-FLAIR mismatch was an exclusion criterion. Our low rate of sICH might be related to our median admission NIHSS score of 7, compared to the ECASS-3 median score of 9; however, 33 of 80 (41%) subjects had admission NIHSS 10. 21 Furthermore, our study's median NIHSS is comparable to another recently completed prospective study of wakeup strokes, with median NIHSS of 6.5. 25 Like the CT-based study, our requirement for qDFM SIR < 1.15 might have excluded patients with more severe strokes, which could have improved the safety profile of alteplase in these patients.
Other prospective studies involving subjects with unwitnessed symptom onset that required perfusion mismatch 29, 30, 32 and/or arterial occlusion visible on vessel imaging 28,31 had more severe median NIHSS scores ranging from 12 to 18. We specifically designed the study not to a priori exclude milder strokes (NIHSS 4), because patients presenting with milder but disabling strokes may also benefit from thrombolysis. 33, 34 Our design enriched the study population in 2 ways: by extending treatment up to 4.5 hours from the time of symptom discovery, and by including both wakeup and nonwakeup unwitnessed strokes. The median time from when the patient was last known to be well to treatment in our study was >11 hours, a time at which the pooled meta-analysis of IV thrombolysis trials 35 suggests an unfavorable benefit to harm ratio.
Although we have no concurrent controls, comparison to the alteplase arms of the major clinical alteplase trials and registries suggests comparable rates of benefit and harm. The presence of qDFM supports our hypothesis that in our enrolled subjects with stroke of unwitnessed symptom onset, the true symptom onset was likely close in time to the discovery of symptoms. A substantial percentage of AIS patients present with uncertain time of symptom onset. Among all subjects with unwitnessed symptom onset, most are wakeup strokes. In our study, the ratio of wakeup to nonwakeup strokes was 2.5:1. Studies have found that 13% to 27% of all patients with stroke awaken with symptoms, making unwitnessed stroke a sizeable public health burden. 36, 37 Because symptom onset is more frequent in the morning, and brain imaging in unwitnessed wakeup strokes is indistinguishable from that in patients with known symptom onset 3 hours previous, waking up with symptoms may be a biomarker of symptom onset. 38, 39 Many patients with wakeup stroke are likely to have a true symptom onset that is within the window in which IV alteplase has been proven effective. Thus, IV alteplase in wakeup stroke could benefit a large proportion of patients and significantly reduce long-term disability. Recent clinical trial data suggest a strong benefit from endovascular thrombectomy for subjects with unwitnessed symptom onset and documented ICA/M1 LVOs, 6 many of whom had wakeup strokes.
However, the proportion of patients with nonwakeup unwitnessed strokes may also be increasing (from 10% to 16% over 11 years) according to a single center report. 40 These nonwakeup unwitnessed stroke patients who did not receive IV alteplase had significantly higher baseline stroke severity, higher rates of in-hospital mortality, and poorer functional outcome at 6 months compared to wakeup unwitnessed strokes. 40 Nonwakeup unwitnessed stroke patients are therefore also in need of effective interventions and are important to include in randomized trials of unwitnessed strokes. These patients are also in need of an acute treatment if they do not have LVOs or meet other criteria for endovascular thrombectomy. We found that although aICH was identified frequently at 24 hours, it was not significantly associated with outcome. This may have been due to competing effects of improvement and worsening, or simply to a lack of influence. Our sample size is too small to explore this further. We did investigate predictors of aICH and found that despite several univariate associations, only the NIHSS score remained significant in the multiple regression model, with an OR of 1.22 for each 1-point increase in the score.
The proportion of good outcome in MR WIT-NESS was 38.8%. It is challenging to identify an appropriate comparison group for our trial in terms of good outcomes, due to the dramatically longer time window and our use of MRI to select subjects. The proportion of good clinical outcome following IV alteplase in the 3-to 4.5-hour window among recent randomized trials or observational cohorts that report the proportion of subjects achieving an mRS of 0-1 at 90 days ranges from 35% in the pooled meta-analysis alteplase cohort (which included subjects up to age 85 years) to 41% in the Safe Implementation of Treatment in Stroke International  Stroke Thrombolysis Register  41 (open label, single arm) and 52% in the ECASS-3 trial. Our observed proportion of 39% lies within this range. We explored factors associated with clinical efficacy and found that prestroke disability, lacunar subtype, current smoking, and higher initial NIHSS score all reduced odds of a good outcome. When we excluded subjects with prestroke mRS > 1 as has been the case in most trials of IV thrombolysis, the proportion of good outcome was 43.5%. We examined the covariates of presence of LVO or the time from symptom onset, measured either as time since patient was last well or time from symptom discovery, and their association with good outcome. Among subjects who had vessel imaging performed, those without LVO had better odds of achieving a good outcome (OR 5 4.02, p 5 0.045), consistent with data suggesting IV alteplase is more effective in distal than proximal occlusions. Duration from symptom onset was not associated with outcome, either because the true biological duration of the strokes was similar in those with a good versus poor outcome, or because other factors are much more important, such as initial NIHSS and the diagnosis of lacunar stroke. Although increasing NIHSS score has been shown to be the most powerful predictor of inpatient mortality and worse outcomes, the data on association between lacunar subtype or cigarette smoking and outcome are mixed. 42 Two large European registry studies and the Third International Stroke Trial did not find a difference in alteplase response comparing lacunar versus nonlacunar strokes. 43, 44 Although it is possible that thrombi in patients with lacunar stroke are less susceptible to thrombolysis compared to other stroke subtypes, there is no clinical trial evidence to support this. It is possible that lacunar infarction in a subgroup of mildly effected subjects is associated with a high proportion of excellent outcomes and that the absolute percentage benefit with IV alteplase is so small that it could not be seen in our study. The recent results of the PRISMS (Study of the Efficacy and Safety of Alteplase in Participants with Mild Stroke) trial recently presented in abstract form showed no difference in the response rates among patients with nondisabling deficits and suggests that IV alteplase is not beneficial in these patients. All subjects in MR WIT-NESS were required to have a deficit that the investigator felt would be disabling, and thus these data reinforce the importance of excluding subjects with nondisabling deficits. Our study has several important limitations. It was a phase 2a open-label single arm safety study, and therefore we have no concurrent randomized controls for comparing safety or efficacy to a placebo arm. The small sample size was determined to assess safety but not efficacy. Our open-label design presents a risk of unconscious bias at the site for assessment of adverse events and poor outcomes despite the use of independent raters. Our use of an independent medical monitor to adjudicate all cases of ICH mitigates the risk of bias in the primary outcome. Our use of MRI in selecting subjects permitted exclusion of patients with large infarction and minimized enrollment of stroke mimics but might limit generalizability. Although we suspect that lack of FLAIR signal suggests potential reversibility of ischemia with reperfusion, we are unable to test this hypothesis. Most patients did not have both pre-and posttreatment vessel and perfusion imaging, limiting our ability to assess reperfusion or recanalization rates. Our study enrolled subjects at a rate of just >3 patients per year, which might be viewed as slow given the estimates of the prevalence of this population among acute ischemic strokes. The rapid enrollment rates of the 2 endovascular trials of late window subjects suggests that with vigilant screening, there will be an abundant number of subjects who may be eligible for IV thrombolysis. Among those with vessel imaging in our study, only 22.9% exhibited an LVO potentially treatable with endovascular thrombectomy. This suggests that with large scale, 24-7 screening at stroke centers, there may be >4 treatable non-LVO subjects for every LVO subject identified. Lastly, our imaging assessment did not use perfusion imaging for patient selection, and so we are limited in our ability to speculate on the influence of this method on safety or efficacy. Although this method has been shown to select patients with LVO who benefit from thrombectomy in late windows, the nature and biology of stroke progression in these patients may be entirely different than in the non-LVO cohort, and it remains to be seen whether it is a useful and reliable tool in selecting patients with more distal occlusions who can still benefit from IV thrombolysis. Although the predominant effect of thrombolysis on outcome in LVO patients may be immediate reperfusion of a large region of reversible ischemia, in smaller infarcts thrombolysis may provide benefit in additional ways, such as preserving the microcirculation or preventing propagation of ischemia into areas that are not initially affected.
In conclusion, MR WITNESS confirms the safety of alteplase in qDFM-selected patients with stroke of unwitnessed symptom onset, and our promising preliminary efficacy data warrant further exploration in a double-blinded RCT of IV alteplase in the broad population of both wakeup and nonwakeup strokes. We have shown that it is feasible to enroll subjects using qDFM, and others have shown similar success with CT-based strategies, laying the groundwork for randomized trials of the efficacy of thrombolysis in MRI-or CT-based selection of patients with stroke of unwitnessed symptom onset. These proposed IV thrombolysis trials would complement the recent successes in endovascular treatment of wakeup strokes with LVOs, 6, 7 because the majority of subjects who were enrolled in MR WITNESS would not have been eligible for these endovascular stroke treatment trials as they lacked LVOs. Non-LVO patients, although likely to have milder strokes, may still benefit from thrombolysis. A new day is dawning in AIS reperfusion therapy for patients with unwitnessed symptom onset who are beyond the traditional, guideline-recommended time windows. The current safety trial is an important step toward ensuring that the subjects with unwitnessed symptom onset and without ICA/M1 LVOs are not excluded from potentially valuable treatment opportunities. Further research testing the efficacy of IV alteplase in subjects with unwitnessed symptom onset is warranted. CT-based selection is more widely available and simpler to execute, but CT is less sensitive to early infarction and so likely enrolls a greater proportion of mimics. MRI, although less readily available and harder to execute, is exquisitely sensitive and specific for infarction. The longer time to imaging with MRI may offset the greater accuracy, and so both methods should be investigated to determine whether the benefit is equally present in both modalities. A prospective randomized trial of late window subjects selected by CT or MRI is warranted.
